AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Phase II Trial Results Of Therapeutic Vaccine Are Encouraging.(Brief Article)
2001 NOV 7 - (NewsRx.com & NewsRx.net) -- Xenova Group plc (XNVA), had announced results from the Phase II clinical efficacy trial conducted in collaboration with its partner, GlaxoSmithKline (GSK), with TA-HSV, a therapeutic vaccine designed for the treatment of genital herpes.
Analysis has shown that the trial has not met its clinical endpoints. The multicenter, placebo-controlled study was conducted among 483 herpes simplex virus (HSV)-2 seropositive patients with symptomatic recurrent genital herpes. No significant difference was seen between the treatment arm and the control group with respect to time to first recurrence, the total number of recurrences or other clinical outcomes assessed during the course of the study. Further development by GSK of the therapeutic vaccine TA-HSV is not planned and the TA-HSV development agreement between the two companies will be terminated effective January 2002.
Xenova will continue to develop DISC-PRO, a prophylactic vaccine designed to prevent genital and orolabial herpes. Xenova holds all rights to DISC-PRO.
...- Phase II Trial Results Of Therapeutic Vaccine Are Encouraging.(Xenova Group PLC...
- Newspaper article from: Immunotherapy Weekly November 7, 2001 700+ words
...with TA-HSV, a therapeutic vaccine designed for the treatment...development by GSK of the therapeutic vaccine TA-HSV is not planned...continue to develop DISC-PRO, a prophylactic vaccine...all rights to DISC-PRO. Phase I results using...
- Preclinical Update - Debio-0512 Therapeutic Vaccine for the Treatment of...
- Press release article from: PR Newswire March 12, 2007 700+ words
...Debio-0512 as an anti-TNFa therapeutic vaccine, that inhibits inflammatory...TNFa is a well-established pro-inflammatory mediator. In...animals receiving the Debio-0512 therapeutic vaccine developed high levels of anti...
- Cerus Announces Scientific Advisory Board for Therapeutic Vaccine Development.
- Press release article from: Business Wire April 28, 2004 700+ words
...and development related to Cerus' therapeutic vaccine program for cancer and infectious disease...Microbiology and Immunology. ABOUT CERUS' THERAPEUTIC VACCINE PROGRAM Cerus is developing proprietary...Cerus scientists have demonstrated that pro
- Biomira presents cancer therapeutic vaccine data.
- Press release article from: Business Wire February 14, 1995 700+ words
...clinical trials of THERATOPE (R) therapeutic vaccine. The presentation, entitled Active...comparators, reveals THERATOPE (R) therapeutic vaccine to be as good as or possibly better...clinical trials using THERATOPE (R) therapeutic vaccine, where mature data on 40 patients...
- Oxxon Therapeutics HI-8(TM) HBV Therapeutic Vaccine Proves Safe and Efficacious...
- Press release article from: PR Newswire April 27, 2006 700+ words
...study of its novel Hi-8(TM) HBV therapeutic vaccine treatment for patients with chronic...that Oxxon's Hi-8(TM) HBV therapeutic vaccine is well tolerated and is capable...evaluation of the Hi-8(TM) HBV therapeutic vaccine in a larger Phase IIb trial. John...
- The Immune Response Corporation Presents Rheumatoid Arthritis Phase IIb Data...
- Press release article from: PR Newswire November 15, 1999 700+ words
...after the third injection of IR501 Therapeutic Vaccine using the ACR 20 criteria for improvement...after multiple injections of the therapeutic vaccine," Dr. Matsumoto said. "Future...treatment formulation, designated IR703 Therapeutic Vaccine, plus adjuvant placebo control...
- 'Therapeutic vaccine for AIDS by 2012'.
- News wire article from: PTI - The Press Trust of India Ltd. October 7, 2008 700+ words
'Therapeutic vaccine for AIDS by 2012' London...predicted that there would be a "therapeutic vaccine" for AIDS by 2012. Montagnier...be possible in future with a therapeutic vaccine for which the results might...
- Oxxon Therapeutics' Hi-8(TM) MEL Therapeutic Vaccine Demonstrates Potential for...
- Press release article from: PR Newswire June 6, 2006 700+ words
...study of its novel Hi-8(TM) MEL therapeutic vaccine in patients with advanced non...with Oxxon's Hi-8(TM) MEL therapeutic vaccine is well tolerated at all doses and...Development of an effective therapeutic vaccine for patients with advanced melanoma...